Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real‐World Observational Study ( FOSAPO )
Movement Disorders Clinical Practice · 2025-12 · 12 (12) · 2330-2336
DOI: 10.1002/mdc3.70254 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 24.07.2025. Verfasst von Clément Desjardins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Foundation Rothschild Hospital, Paris, France. Hauptthemen laut MEDLINE: Parkinson Disease, Apomorphine, Antiparkinson Agents, Carbidopa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Continuous subcutaneous foslevodopa/foscarbidopa (CSFLI) is emerging as a new treatment for advanced Parkinson's disease (APD), but its efficacy and safety as a second‐line infusion therapy in patients previously treated with apomorphine remain to be clarified.
Objectives
The aim of this study was to evaluate the short‐term clinical impact of switching from continuous subcutaneous apomorphine infusion (CSAI) to CSFLI in a real‐world cohort.
Methods
We conducted a retrospective observational study including 14 patients with APD who transitioned from CSAI to CSFLI. Clinical assessments were performed at baseline (M0) and 3 months after the switch (M3).
Results
At M3, motor complications (Movement Disorder Society‐the Unified Parkinson's Disease Rating Scale [MDS‐UPDRS Part IV]) were significantly reduced, with improvements in functional scores (Part II), quality of life (Parkinson's Disease Questionnaire‐8 [PDQ‐8]), clinical global impression of severity (CGI‐S), and neuropsychiatric inventory (NPI). No patient discontinued treatment. Two patients developed de novo apathy.
Conclusion
Switching from CSAI to CSFLI is feasible, effective, and well tolerated. Behavioral changes observed in two cases underline the need for clinical awareness when treating patients with subtle cognitive vulnerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Foundation Rothschild Hospital, Paris, France.
ORCID-Profile: Clément Desjardins
Zitieren
APA
Desjardins, C., Salardaine, Q., Brandel, J. P., & Baille, G. (2025). Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real‐World Observational Study ( FOSAPO ). Movement Disorders Clinical Practice, 12(12), 2330-2336. https://doi.org/10.1002/mdc3.70254
Vancouver
Desjardins C, Salardaine Q, Brandel JP, Baille G. Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real‐World Observational Study ( FOSAPO ). Movement Disorders Clinical Practice. 2025;12(12):2330-2336. doi:10.1002/mdc3.70254
BibTeX
@article{Desjardins2025,
author = {Desjardins, Clément and Salardaine, Quentin and Brandel, Jean-Philippe and Baille, Guillaume},
title = {Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real‐World Observational Study ( FOSAPO )},
journal = {Movement Disorders Clinical Practice},
year = {2025},
volume = {12},
number = {12},
pages = {2330--2336},
doi = {10.1002/mdc3.70254}
}
EUVIMED